USFDA issues Form 483 with 6 observations to Enzene Biosciences’ Chakan plant following PAI

The Pre-Approval Inspection (PAI) was completed on February 13, 2026, and the company is initiating corrective actions.

Novartis’ Vanrafia shows promise in slowing kidney decline in IgA nephropathy

Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN

PathoCare Holdings valued at $1.75 billion following major third-party tender offer

The company previously completed a $150 million venture investment, acquisition, and recapitalization

Diamyd Medical accelerates Phase 3 Type 1 diabetes trial following FDA guidance

The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026

GSK strikes deal with US to lower prescription drug costs & boost respiratory medicine access

GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%

Merck strikes historic deal with Trump admin to lower drug costs for Americans

Merck KGaA launches ChemiSphere App to digitize lab workflows

The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences

Godavari Biorefineries ED Sangeeta Srivastava named BRSI Honorary Fellow

Dr Srivastava was selected by an expert jury in recognition of her sustained contributions to renewable chemicals, industrial biotechnology and bioprocess innovation

Bayer reports promising results for low-dose pediatric MRI contrast agent

MRI is particularly valuable in pediatric care due to its non-invasive nature

Amrutanjan re-launches its iconic yellow balm

Amrutanjan is also rolling out its new campaign, 'Har Dard Mitaye'